JP7518316B1 - テネリグリプチン含有粒子及びそれを含む製剤 - Google Patents

テネリグリプチン含有粒子及びそれを含む製剤 Download PDF

Info

Publication number
JP7518316B1
JP7518316B1 JP2024506590A JP2024506590A JP7518316B1 JP 7518316 B1 JP7518316 B1 JP 7518316B1 JP 2024506590 A JP2024506590 A JP 2024506590A JP 2024506590 A JP2024506590 A JP 2024506590A JP 7518316 B1 JP7518316 B1 JP 7518316B1
Authority
JP
Japan
Prior art keywords
teneligliptin
acid
porous silica
containing particles
silicon dioxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024506590A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2024171708A1 (https=
JPWO2024171708A5 (https=
Inventor
卓朗 西村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sawai Pharmaceutical Co Ltd
Original Assignee
Sawai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sawai Pharmaceutical Co Ltd filed Critical Sawai Pharmaceutical Co Ltd
Priority claimed from PCT/JP2024/001234 external-priority patent/WO2024171708A1/ja
Application granted granted Critical
Publication of JP7518316B1 publication Critical patent/JP7518316B1/ja
Publication of JPWO2024171708A1 publication Critical patent/JPWO2024171708A1/ja
Publication of JPWO2024171708A5 publication Critical patent/JPWO2024171708A5/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024506590A 2023-02-13 2024-01-18 テネリグリプチン含有粒子及びそれを含む製剤 Active JP7518316B1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023020036 2023-02-13
JP2023020036 2023-02-13
PCT/JP2024/001234 WO2024171708A1 (ja) 2023-02-13 2024-01-18 テネリグリプチン含有粒子及びそれを含む製剤

Publications (3)

Publication Number Publication Date
JP7518316B1 true JP7518316B1 (ja) 2024-07-17
JPWO2024171708A1 JPWO2024171708A1 (https=) 2024-08-22
JPWO2024171708A5 JPWO2024171708A5 (https=) 2025-01-22

Family

ID=91895935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024506590A Active JP7518316B1 (ja) 2023-02-13 2024-01-18 テネリグリプチン含有粒子及びそれを含む製剤

Country Status (2)

Country Link
JP (1) JP7518316B1 (https=)
CN (1) CN118804750A (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020070260A (ja) * 2018-10-31 2020-05-07 沢井製薬株式会社 テネリグリプチン含有医薬組成物、テネリグリプチン含有医薬組成物の製造方法、テネリグリプチン含有錠剤及びテネリグリプチン含有錠剤の製造方法
JP2021161096A (ja) * 2020-04-03 2021-10-11 金剛化学株式会社 テネリグリプチン塩のアモルファス形態及びその製造方法
JP2023056991A (ja) * 2021-10-08 2023-04-20 日本ジェネリック株式会社 テネリグリプチン含有医薬組成物
JP2023156269A (ja) * 2022-04-12 2023-10-24 日本ジェネリック株式会社 テネリグリプチン含有医薬組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020070260A (ja) * 2018-10-31 2020-05-07 沢井製薬株式会社 テネリグリプチン含有医薬組成物、テネリグリプチン含有医薬組成物の製造方法、テネリグリプチン含有錠剤及びテネリグリプチン含有錠剤の製造方法
JP2021161096A (ja) * 2020-04-03 2021-10-11 金剛化学株式会社 テネリグリプチン塩のアモルファス形態及びその製造方法
JP2023056991A (ja) * 2021-10-08 2023-04-20 日本ジェネリック株式会社 テネリグリプチン含有医薬組成物
JP2023156269A (ja) * 2022-04-12 2023-10-24 日本ジェネリック株式会社 テネリグリプチン含有医薬組成物

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
上田廣，非晶質：Co-amorphousの研究動向，難水溶性薬物の経口製剤化技術最前線，2016年，第１版，p.118-126
上田廣: "非晶質：Co-amorphousの研究動向", 難水溶性薬物の経口製剤化技術最前線, vol. 第１版, JPN6024013797, 2016, pages 118 - 126, ISSN: 0005305792 *
中本敬三，製剤中における医薬品化合物の結晶・非晶質状態の評価，薬剤学，2015年，Vol.75, No.3，p.145-153
中本敬三: "製剤中における医薬品化合物の結晶・非晶質状態の評価", 薬剤学, vol. 75, no. 3, JPN6024013796, 2015, pages 145 - 153, ISSN: 0005305793 *
岡野定舗, 新・薬剤学総論, vol. 改訂第３版, JPN6024013800, pages 359 - 363, ISSN: 0005305796 *
岡野定舗，新・薬剤学総論，改訂第３版，p.359-363
森部久仁一，多孔性シリカを用いた有機・無機ハイブリット機能性薬物放出担体の開発，日本板硝子材料工学助成会 成果報告書，2001年，39，p.189-193
森部久仁一: "多孔性シリカを用いた有機・無機ハイブリット機能性薬物放出担体の開発", 日本板硝子材料工学助成会 成果報告書, vol. 39, JPN6024013799, 2001, pages 189 - 193, ISSN: 0005305795 *
竹内洋文 ほか，多孔性微粒子担体を用いた薬物固体分散体粒子の設計，粉体工学会誌，2003年，Vol.40, No.3，p.157-162
竹内洋文 ほか: "多孔性微粒子担体を用いた薬物固体分散体粒子の設計", 粉体工学会誌, vol. 40, no. 3, JPN6024013798, 2003, pages 157 - 162, ISSN: 0005305794 *

Also Published As

Publication number Publication date
JPWO2024171708A1 (https=) 2024-08-22
CN118804750A (zh) 2024-10-18

Similar Documents

Publication Publication Date Title
US8877238B2 (en) Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound
JP7117975B2 (ja) テネリグリプチン含有医薬組成物、テネリグリプチン含有医薬組成物の製造方法、テネリグリプチン含有錠剤及びテネリグリプチン含有錠剤の製造方法
EP4147689A1 (en) Lenvatinib formulation
JP6639024B2 (ja) 化学的な安定性を改善した、非晶質体ソリフェナシン含有製剤
JP2018154596A (ja) アジルサルタン含有固形医薬組成物
KR20190045286A (ko) 로수바스타틴 및 에제티미브를 포함하는 제약 조성물 및 그의 제조 방법
JP6446511B2 (ja) 非晶質体ソリフェナシン及び抗酸化剤を含有する固形製剤
CN102026626B (zh) 包含草酸艾司西酞普兰的颗粒
JP7518316B1 (ja) テネリグリプチン含有粒子及びそれを含む製剤
EP2101742B1 (en) Pharmaceutical composition containing clopidogrel hydrogenesulphate of polymorph 1 form
EP3731817B1 (en) Pharmaceutical composition of lenalidomide pharmaceutically acceptable acid addition salt
JP7799904B2 (ja) テネリグリプチン含有製剤
WO2024171708A1 (ja) テネリグリプチン含有粒子及びそれを含む製剤
KR20210096162A (ko) 의약 조성물
JP2018177789A (ja) コハク酸ソリフェナシン含有固形医薬組成物
JP7271869B2 (ja) レボセチリジン含有錠剤
JP6272328B2 (ja) カンデサルタンシレキセチル含有製剤
RU2857663C2 (ru) Фармацевтическая композиция, содержащая пимитеспиб
EP4260848A1 (en) Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
CN116322653B (zh) 包括酞嗪酮衍生物的药物组合物
KR20180003340A (ko) 무정형 솔리페나신 함유 경구용 고형제제 및 그 제조방법
EP4401708A1 (en) Pharmaceutical composition of bempedoic acid
WO2023238929A1 (ja) ピミテスピブを含有する医薬組成物
JP2022151564A (ja) 薬効成分としてビルダグリプチンおよびメトホルミンを含む錠剤
JP2022547307A (ja) インドールアミン２，３－ジオキシゲナーゼ阻害剤の医薬製剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240201

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240605

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240702

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240704

R150 Certificate of patent or registration of utility model

Ref document number: 7518316

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150